NCT02293798已完成不适用
Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold
Mark Mofid MD1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2014年8月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Number of Participants With Areolar Dilation of up to 6mm at 12 Months
研究概览
简要总结
The purpose of this study is to evaluate the clinical performance of SERI® Surgical Scaffold to maintain the size of the areola by providing additional soft tissue support after circumferential periareolar mastopexy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female, age 18 years or older desiring a reduction in size of nipple areola complex
- •Be in good health and suited to general anesthesia and planned treatments
- •Non smokers
- •If the subject is of childbearing potential, have a urine pregnancy test evaluated as negative (assessed at baseline examination (Visit 1), agree to use contraception as prevention to avoid pregnancy during the study period
- •Previous augmentation with silicone-filled or saline-filled breast implants or patients desiring periareolar mastopexy
- •Requiring surgery for ptotic breasts
排除标准
- •BMI (Body Mass Index) that is ≥ 30 kg/m2
- •Active smoker or have smoked within 6 weeks prior to screening/qualification visit (Visit 1)
- •Pregnant or nursing
- •Advanced fibrocystic disease considered to be premalignant without accompanying subcutaneous mastectomy
- •Previous mastectomy or lumpectomy
- •Abscess or infection in the body at the time of enrollment
- •Had any disease, including uncontrolled diabetes (e.g., HbAIc > 8%), that is clinically known to impact wound healing ability. For example: collagen-vascular, connective tissue or autoimmune disorders (e.g., Systemic Lupus, Rheumatoid Arthritis, Scleroderma)
- •Subjects with diagnosed diabetes must have HbAIc ≤ 8% within 3 months of enrollment
- •Is taking medications known to impair wound healing (e.g. corticosteroids, chemotherapeutic agents etc.,)
- •Bleeding disorders (e.g., Hemophilia, von Willebrand Disease) including the following medications & supplements: Warfarin, platelet inhibitors (e.g. NSAIDs or Clopidogrel) not stopped within 2 weeks of the operation and herbal supplements known to predispose to bleeding (e.g. Gingko and Ginseng)
- •Showed tissue characteristics that were clinically incompatible with mammaplasty, such as tissue damage resulting from radiation, inadequate tissue, compromised vascularity or ulceration
- •Had, or was under treatment for, any condition that may have constituted an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems)
- •History of prior implantation of any surgical scaffold (e.g., synthetic mesh, acellular dermal matrix, or biologic mesh) in the breast
- •Implantation of any non-SERI® surgical scaffold (e.g., synthetic mesh, acellular dermal matrix, or biologic mesh) during the study period
- •Be currently enrolled in another clinical study of an implanted device in the breast or plan to enroll in another clinical study within the study period, which could affect wound healing in the breast repair site and/or would not allow the patient to attend all study visits as outlined within this protocol
- •Product contraindications for use of SERI® Surgical Scaffold per the supplied package insert (e.g., hypersensitivity to silk)
- •Show psychological characteristics that may have been incompatible with the surgical procedure and the prosthesis, such as inappropriate attitude or motivation (e.g., body dysmorphic disorder)
- •Active alcohol/substance abuse problem or have had a relapse within 1 year prior to screening/qualification visit (Visit 1)
- •Was not willing to undergo further surgery for revision, if medically required
研究组 & 干预措施
SERI
Experimental
Subjects receiving SERI for mastopexy
干预措施: silk surgical scaffold (Device)
结局指标
主要结局
Number of Participants With Areolar Dilation of up to 6mm at 12 Months
时间窗: 12 months after SERI implantation
areolar dilation of up to 6mm
次要结局
未报告次要终点
研究者
Mark Mofid MD
Principal Investigator
Mofid, Mehrdad Mark, M.D.
研究点 (1)
Loading locations...
相似试验
已完成
不适用
SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation SurgerySubjects Requiring Revision Breast Augmentation SurgeryNCT02030938Sofregen Medical, Inc.34
终止
不适用
SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia RepairVentral Hernia RepairNCT01981044Sofregen Medical, Inc.1
已完成
不适用
The SERI® Surgical Scaffold Use in Reconstruction Post Market Study for Tissue Support and Repair in Breast Reconstruction SurgeryBreast ReconstructionNCT01256502Sofregen Medical, Inc.160
已完成
不适用
SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast ReconstructionBreast ReconstructionNCT01914653Sofregen Medical, Inc.17
Unknown
不适用
Periareolar Approach in Minimally Invasive Cardiac SurgeryPeriareolar Minimally Invasive Cardiac SurgeryNCT04726488Assiut University102